Modality
Fusion Protein
MOA
EGFRi
Target
SGLT2
Pathway
STING
Schizophrenia
Development Pipeline
Preclinical
~Jan 2014
→ ~Apr 2015
Phase 1
~Jul 2015
→ ~Oct 2016
Phase 2
~Jan 2017
→ ~Apr 2018
Phase 3
Jul 2018
→ Jun 2025
Phase 3Current
NCT08536522
1,448 pts·Schizophrenia
2018-07→2025-06·Completed
1,448 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-06-279mo agoPh3 Readout· Schizophrenia
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3
P3
Complet…
Catalysts
Ph3 Readout
2025-06-27 · 9mo ago
Schizophrenia
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08536522 | Phase 3 | Schizophrenia | Completed | 1448 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Niranesiran | Johnson & Johnson | Phase 2 | KIF18A | |
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| GSK-2051 | GSK | Phase 1 | PSMA | |
| DSN-7360 | Daiichi Sankyo | Approved | SGLT2 | |
| GIL-8529 | Gilead Sciences | Phase 1/2 | JAK1 | |
| SRP-3270 | Sarepta | Phase 1/2 | SGLT2 | |
| Tirarapivir | United Therapeutics | Approved | SGLT2 |